Meschia J F, Williams L S, Fleck J D, Bruno A, Biller J
Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.
J Stroke Cerebrovasc Dis. 1999 Jul-Aug;8(4):207-10. doi: 10.1016/s1052-3057(99)80068-8.
Indiana emergency medicine physicians and neurologists were presented with 6 brief cases of patients presenting with acute ischemic stroke and asked whether they would administer tissue plasminogen activator (t-PA) in each case; 25% responded in concordance with published American Heart Association guidelines in all cases. Only 19% gave the appropriate exclusion in the 4 cases with definite exclusion criteria. Administering t-PA to a patient with elevated blood pressure was the most common deviation from the guidelines. More neurologists reported that they would have given t-PA in the exclusion-free scenario (85% v 49%; P<.001). Physicians likely to treat acute stroke patients do not consistently follow published guidelines on the use of intravenous t-PA in acute ischemic stroke. Neurologists were more likely to report that they would use t-PA in an exclusion-free scenario. Continued physician education about thrombolytic use in acute ischemic stroke is needed.
印第安纳州的急诊医学医生和神经科医生收到了6例急性缺血性中风患者的简短病例,并被问及他们是否会在每种情况下使用组织纤溶酶原激活剂(t-PA);25%的人在所有病例中都按照美国心脏协会公布的指南做出了回应。在4例有明确排除标准的病例中,只有19%进行了适当的排除。给血压升高的患者使用t-PA是最常见的违反指南的情况。更多的神经科医生报告说,他们会在无排除标准的情况下使用t-PA(85%对49%;P<.001)。可能治疗急性中风患者的医生并没有始终遵循关于在急性缺血性中风中使用静脉注射t-PA的已公布指南。神经科医生更有可能报告说他们会在无排除标准的情况下使用t-PA。需要持续对医生进行关于急性缺血性中风中溶栓使用的教育。